|
|
LATS2 |
large tumor suppressor kinase 2 |
|
|
|
|
|
LENG1 |
leukocyte receptor cluster member 1 |
|
|
|
|
|
MAP2K5 |
mitogen-activated protein kinase kinase 5 |
|
|
|
|
|
MAPK14 |
mitogen-activated protein kinase 14 |
- NOD1/2 Signaling Pathway
- p38MAPK events
- p38MAPK events
- ERK/MAPK targets
- Activation of PPARGC1A (PGC-1alpha) by phosphorylation
- Oxidative Stress Induced Senescence
- DSCAM interactions
- ADP signalling through P2Y purinoceptor 1
- Platelet sensitization by LDL
- VEGFA-VEGFR2 Pathway
- activated TAK1 mediates p38 MAPK activation
- Activation of the AP-1 family of transcription factors
- KSRP (KHSRP) binds and destabilizes mRNA
- Myogenesis
- Myogenesis
- RHO GTPases Activate NADPH Oxidases
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- CD163 mediating an anti-inflammatory response
|
- Minocycline
- Dasatinib
- 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
- N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
- Inhibitor of P38 Kinase
- 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
- 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
- 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
- 3-(Benzyloxy)Pyridin-2-Amine
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
- 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
- Doramapimod
- 2-Chlorophenol
- 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
- SB220025
- 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
- Triazolopyridine
- KC706
- Talmapimod
- VX-702
- R-1487
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
- N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
- Neflamapimod
- N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
- 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
- 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
- N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
- 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
- 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
- N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
- N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
- N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
- PH-797804
- 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
- SD-0006
- N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
- N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
- 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
- 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
- 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
- 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
- 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
- N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
- N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
- N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
- 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
- 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
- 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
- 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
- Fostamatinib
|
|
|
|
MSN |
moesin |
- Recycling pathway of L1
- Recycling pathway of L1
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
|
|
|
|
|
MYLIP |
myosin regulatory light chain interacting protein |
- VLDLR internalisation and degradation
- NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
|
MYOZ3 |
myozenin 3 |
|
|
|
|
|
PATL1 |
PAT1 homolog 1, processing body mRNA decay factor |
- mRNA decay by 5' to 3' exoribonuclease
- mRNA decay by 5' to 3' exoribonuclease
|
|
|
|
|
PATZ1 |
POZ/BTB and AT hook containing zinc finger 1 |
|
|
|
|
|
PLK1 |
polo like kinase 1 |
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Polo-like kinase mediated events
- Golgi Cisternae Pericentriolar Stack Reorganization
- Golgi Cisternae Pericentriolar Stack Reorganization
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Phosphorylation of the APC/C
- Phosphorylation of Emi1
- Condensation of Prophase Chromosomes
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- Regulation of PLK1 Activity at G2/M Transition
- Activation of NIMA Kinases NEK9, NEK6, NEK7
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Anchoring of the basal body to the plasma membrane
- RHO GTPases Activate Formins
- Mitotic Prometaphase
- Mitotic Metaphase/Anaphase Transition
- Mitotic Telophase/Cytokinesis
- Cyclin A/B1/B2 associated events during G2/M transition
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- EML4 and NUDC in mitotic spindle formation
|
- 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol
- 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide
- 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
- 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea
- Wortmannin
- Fostamatinib
|
|
|
|
PLK2 |
polo like kinase 2 |
- TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
- CD163 mediating an anti-inflammatory response
|
|
|
|
|
POGZ |
pogo transposable element derived with ZNF domain |
|
|
|
|
|
POU6F2 |
POU class 6 homeobox 2 |
|
|
|
|
|
PPP1R18 |
protein phosphatase 1 regulatory subunit 18 |
|
|
|
|
|
PPP1R32 |
protein phosphatase 1 regulatory subunit 32 |
|
|
|
|
|
PRMT6 |
protein arginine methyltransferase 6 |
- RMTs methylate histone arginines
- RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
|
|
|
|
|
RBPMS |
RNA binding protein, mRNA processing factor |
|
|
|
|
|
RDX |
radixin |
- Recycling pathway of L1
- Recycling pathway of L1
|
- 1D-myo-inositol 1,4,5-trisphosphate
|
|
|
|
RHEB |
Ras homolog, mTORC1 binding |
- Macroautophagy
- MTOR signalling
- mTORC1-mediated signalling
- Energy dependent regulation of mTOR by LKB1-AMPK
- TP53 Regulates Metabolic Genes
- Regulation of PTEN gene transcription
- Amino acids regulate mTORC1
|
- Guanosine-5'-Triphosphate
- Guanosine-5'-Diphosphate
|
|
|
|
RIN1 |
Ras and Rab interactor 1 |
- RAB GEFs exchange GTP for GDP on RABs
|
|
|